Statement by Pfizer Chairman and CEO Albert Bourla

New York, NY, January 15, 2021 – Pfizer Inc. (NYSE: PFE) – Today President-elect Biden released a COVID-19 vaccination plan that our scientists reviewed and believe will accelerate our ability to beat back the pandemic and save American lives. This comprehensive federal plan utilizes as many doses as possible, opens up eligibility to a broader set of Americans, and ensures equity by focusing on the hardest hit communities.

We are particularly aligned with the ideas of federally assisted vaccination centers, financial support to the States, mobile clinics to reach underserved urban areas and rural communities, vaccine availability in pharmacies and qualified health centers and an expanded public health workforce.

At Pfizer, we are ready and able to support this plan and look forward to working together to make the light at the end of this long tunnel brighter and closer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com